LivaNova PLC research snapshot
LIVN AI stock analysis currently reads LivaNova as a specialized medical technology company with two operating segments: Neuromodulation (vagus nerve stimulation therapy for drug-resistant epilepsy and depression, plus the newly FDA-approved aura6000 system for obstructive sleep apnea) and Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion systems, and perfusion products). At the July 12, 2026 data cutoff, LIVN traded near $83.58 with a verified market value near $4.59 billion. The bull case depends on aura6000 OSA commercial launch, continued VNS Therapy adoption, positive OSPREY study momentum, cardiopulmonary recovery, margin expansion toward med-tech peer levels, and strong free cash flow generation. The caution is that the stock trades near its 52-week high at 42.86x trailing earnings, TTM EPS of $1.95 includes prior-year restructuring noise, competitive pressure exists in both segments, and the company has a history of CEO turnover and acquisition integration challenges.
Current price
$83.58
Market cap
$4.59 billion verified market cap
AI score
65 / 100
Rating
Niche medical technology company with durable neuromodulation franchises, recovering cardiopulmonary segment, positive clinical data, and meaningful regulatory plus competitive risk
Trend status
Constructive short-term technical trend near 52-week highs, with price well above both 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | LivaNova sells implantable VNS therapy devices for epilepsy and depression, cardiopulmonary bypass products for cardiac surgery, and is launching aura6000 for obstructive sleep apnea. | Medium-high |
| Moat | VNS Therapy has FDA approval, clinical evidence, implanted base, and physician training that create switching costs. Cardiopulmonary products compete on quality and regulatory compliance. aura6000 faces a moat-building challenge against Inspire Medical in OSA. | Medium |
| Management | CEO Vladimir Makatsaria joined in March 2024 with a medical device and pharmaceutical background. The team is relatively new and faces execution tests on aura6000 launch and margin improvement. | Medium |
| Financial trend | FY2025 revenue of $1.39B grew 10.7% YoY but net income was negative $242.5M, likely due to restructuring. Q1 2026 showed revenue growth of 14.3% YoY to $362.3M and net income of $22.3M. TTM net income was $107.1M. | Medium-high |
| Valuation | At $83.58, verified math shows about 42.86x TTM EPS, 3.79x book value, 23.22x FCF per share, and 3.20x sales. Forward P/E of 19.76x reflects expected EPS recovery. | Medium-high |
| Technical trend | The stock trades near its 52-week high with strong upward momentum, up about 86% over the past year. Price is above key moving averages with bullish technical setup. | Medium |
| Risk level | Risk is elevated due to competitive pressure in OSA from Inspire Medical, cardiopulmonary market cyclicality, regulatory risk for VNS and aura6000, pricing pressure from hospital group purchasing, and turnaround execution risk under new management. | Medium |
| AI confidence | Descriptive confidence is high because SEC filing data is available. Forecast confidence is medium because product launch adoption rates, competitive dynamics, and margin trajectory are uncertain. | High data confidence |
| Investment certainty | Investment certainty is medium-low at this price. LIVN has interesting product franchises and a potential growth catalyst in aura6000, but the trailing P/E of 42.86x prices in significant improvement and leaves limited room for execution misses. | Medium-low |
LIVN AI stock forecast
The LIVN AI stock forecast is scenario-based, not a precise price prediction. Using the July 12, 2026 research cutoff, an $83.58 stock price, $1.95 TTM EPS, and considering forward EPS estimates near $4.23, the valuation range depends on aura6000 commercial success, cardiopulmonary recovery, margin trajectory, and the multiple the market assigns.
$115 to $135
More likely if aura6000 OSA commercial launch gains rapid adoption with strong physician and patient uptake, Q2 and Q3 2026 results beat expectations, VNS Therapy maintains steady growth, cardiopulmonary margins expand, and the market assigns a forward P/E of 25x or more on improved earnings power.
$75 to $90
More likely if the forward P/E of 19.76x proves fair, EPS grows as expected through margin improvement and steady revenue growth, Q3 cardiopulmonary seasonality is normal, and the stock trades in a range consistent with medical device mid-cap valuations.
$45 to $60
More likely if aura6000 launch disappoints relative to Inspire Medical competition, VNS Therapy faces pricing pressure or reimbursement changes, cardiopulmonary revenue stagnates, or the company reports EPS or margin misses that cause the forward multiple to contract toward the teens.
LIVN AI technical analysis
LIVN AI technical analysis is constructive as of the July 12, 2026 data cutoff. Yahoo Finance showed a July 7 close at $83.58 with a day range of $82.48 to $84.77, and the 52-week range spans $41.01 to $85.27. Volume of 435,356 on July 7 was below the 805,650 average, suggesting the recent uptrend is not yet overextended. The stock has gained approximately 86% over the past year and is trading near its 52-week high.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $83.58 | Yahoo Finance July 7, 2026 closing quote, used as the reference price for valuation and market-cap math. |
| Immediate support | $75 to $80 | The zone below the July 7 close that covers recent consolidation levels and likely buying interest from institutional investors. |
| Deeper support | $65 to $70 | A pullback to this level would represent a 15-20% correction from the current price, a common retracement zone in uptrends. |
| Near resistance | $85 to $87 | The 52-week high near $85.27 is the immediate overhead resistance. A clean break above this would signal trend continuation. |
| 50-day moving average | Estimated $70 to $75 | With the stock up 86% over the past year, the 50-day MA likely sits well below the current price, providing a far support reference. |
| 200-day moving average | Estimated $58 to $65 | The 200-day MA is significantly below the current price, indicating the stock is in a strong uptrend. |
| Momentum | RSI likely above 60 | The stock is near its 52-week high with strong upside momentum year-to-date, but RSI may be approaching overbought territory. |
| Volume | 435,356 shares on July 7 | Below average volume suggests the current price level has not triggered excessive profit-taking. |
| Volatility | Beta near 0.86 | LIVN has below-market volatility by beta, but product launch announcements, clinical data, and quarterly earnings can still produce sharp moves. |
| Invalidation | Close below $75, then below $65 | A close below $75 would suggest the uptrend is stalling. A move below $65 would put the bear scenario in focus. |
LIVN AI trading strategy
The LIVN AI trading strategy below is a rules-based research framework, not personal financial advice. It links price action with Q2 2026 earnings on August 5, 2026, aura6000 commercial launch data, OSPREY clinical study follow-up, VNS Therapy adoption, cardiopulmonary segment trends, and valuation discipline.
Watch for LIVN to close above the $85 to $87 resistance zone (52-week high area) with volume near or above the 805,650 average while Q2 2026 results confirm revenue growth, margin improvement, and positive aura6000 commercial traction.
Treat a failed breakout above the 52-week high followed by a close below $75 as a warning that the trend may be losing momentum.
If LIVN pulls back toward $75 to $80 without a negative catalyst such as an earnings miss, regulatory setback, or competitive threat, compare the reset price with the forward earnings power and PEG ratio of 0.93x.
Do not average down based on the stock being up 86% in the past year. Require evidence that the growth thesis is intact and the pullback is volume-driven exhaustion rather than fundamental deterioration.
Track Q2 2026 earnings, aura6000 launch metrics, OSPREY study results, VNS Therapy revenue growth, cardiopulmonary segment margins, operating cash flow, debt levels, and forward guidance.
Lower the rating if revenue growth slows below 10% while the stock trades above a 20x forward P/E, or if competitive data from Inspire Medical or other OSA therapies weakens the aura6000 market opportunity.
Investment research summary
Patients and surgeons pay LivaNova because VNS Therapy provides a proven electrical stimulation treatment for drug-resistant epilepsy and depression when medications fail, and cardiopulmonary bypass products are essential equipment for open-heart surgery procedures.
LIVN benefits from FDA-approved VNS technology with clinical evidence and an implanted patient base. Physician training and patient outcomes create switching costs. The moat is being tested in OSA by Inspire Medical, which has a competing hypoglossal nerve stimulation device with a head start in the market.
The thesis fails if aura6000 commercial launch underperforms expectations, Inspire Medical or another competitor dominates the OSA neuromodulation market, VNS Therapy faces reimbursement cuts, cardiopulmonary revenue stagnates, or margin improvement plans fall short of guidance.
CEO Vladimir Makatsaria was appointed in March 2024 and brings experience from Baxter, Abbott, and Johnson & Johnson. The management team is still in the early stages of executing its turnaround strategy, and the company has had prior CEO turnover.
LivaNova operates in beneficial med-tech trends: aging populations driving cardiac surgery volumes, increasing awareness of drug-resistant epilepsy treatment options, and growing demand for non-pharmaceutical OSA treatments. The neuromodulation market is expanding but competitive.
At about 42.86x TTM EPS and 23.22x FCF per share, LIVN is priced for a turnaround. The forward P/E of 19.76x and PEG ratio of 0.93 suggest more reasonable valuation relative to expected growth. Margin of safety is limited at the current price given execution risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| LIVN quote reference | $83.58 closing price as of July 7, 2026, with day range of $82.48 to $84.77 | Yahoo Finance LIVN summary | July 12, 2026 |
| Market capitalization verification | $4.59 billion calculated and reported market cap, verified from $83.58 x 54.93 million shares | Pineify financial_rigor.py and CompaniesMarketCap | July 12, 2026 |
| Shares outstanding | Approximately 54.93 million shares, cross-referenced from market cap divided by share price | Pineify calculation from Yahoo Finance data | July 12, 2026 |
| TTM financial data | $1.43B revenue, $107.14M net income, $1.95 EPS, $3.60 FCF per share, $198.05M levered FCF | Yahoo Finance and WallStreetZen | July 12, 2026 |
| FY2025 annual revenue | $1.39 billion revenue with 10.7% YoY growth | WallStreetZen LIVN revenue history | July 12, 2026 |
| Q1 2026 results | $362.3M revenue (+14.3% YoY), $22.3M net income, $0.41 EPS | WallStreetZen LIVN earnings | July 12, 2026 |
| Balance sheet strength | $539.71M cash and equivalents, 28.35% debt-to-equity ratio | Yahoo Finance LIVN statistics | July 12, 2026 |
| Valuation metrics | 42.86x trailing P/E, 19.76x forward P/E, 0.93 PEG ratio, 3.20x price/sales, 3.79x price/book, 3.07x EV/revenue, 19.52x EV/EBITDA | Yahoo Finance LIVN statistics | July 12, 2026 |
| Profitability and returns | 7.47% profit margin, 5.27% return on assets, 9.54% return on equity | Yahoo Finance LIVN statistics | July 12, 2026 |
| Beta and volatility | Beta of 0.86 on a monthly 5-year basis | Yahoo Finance LIVN summary | July 12, 2026 |
| Technical trend | Stock up approximately 86% over the past year, 52-week range of $41.01 to $85.27 | Yahoo Finance LIVN summary and CompaniesMarketCap | July 12, 2026 |
| CEO and management context | Vladimir Makatsaria was appointed CEO and board director on March 1, 2024; Alex Shvartsburg serves as CFO | Wikipedia LivaNova page | July 12, 2026 |
This LIVN AI stock analysis page is an informational research tool only and is not investment advice, a recommendation, or a promise of future return. Forecast scenarios are based on public data available at the stated cutoff date, use simplified assumptions, and can be wrong if business, market, regulatory, clinical, or valuation conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
